Susan Scott, MD

The Johns Hopkins Hospital

Latest Videos

Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC - OncUpdates featuring Dr. Julia Rotow, Dr. Fawzi Abu Rous, Dr. Sarah Goldberg, and Dr. Susan Scott discussing recent advances in.

Roundtable

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD

Proactive toxicity management and CNS control in EGFR-mutant NSCLC discussed by leading oncologists at OncUpdates conference. Expert insights on personalized treatment strategies.

Roundtable

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD

OS Benefit and Patient-Centered Delivery Advances in EGFR-Positive NSCLC, featuring Dr. Eric Singhi, Dr. Julia Rotow, Dr. Susan Scott, Dr. Sarah Goldberg, and Dr. Fawzi Abu Rous discussing recent onco.

Roundtable

03/14/2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MDSusan Scott, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MD

Innovative oncology discussion featuring medical experts sharing insights on cancer treatment strategies at OncUpdates conference.

ASCO 2025

06/16/2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MDEstelamari Rodriguez, MD, MPHHelena Yu, MD

Frontline treatment for metastatic EGFR-mutated NSCLC discussed by leading oncologists at OncUpdates, featuring Dr. Susan Scott, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Videos & Podcasts

06/16/2025

Frontline Treatment for Metastatic EGFR-Mutated NSCLC

Susan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD

Mariposa: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC - Oncology research featuring leading doctors discussing advanced lung cancer treatment options and targeted therapies.

ASCO 2025

06/15/2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MDSusan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates latest research on targeted therapies for metastatic non-small cell lung cancer involving genetic mutations and personalized treatment options.

Videos & Podcasts

05/28/2025

Selecting Up-Front Treatments for NSCLC with Targetable Mutations

Susan Scott, MD